Identifying stocks to buy and hold for decades rather than months or years can be difficult. The world and the economy are constantly changing, creating risks for long-term investors.

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

Merck's growing pipeline, with nearly 20 new launches ahead, is set to reshape its portfolio as Keytruda's 2028 patent expiry ...

Acquisition by Merck KGaA The most significant recent development for SpringWorks is the agreement by Merck KGaA to acquire the company at $47 per share.

Merck & Co., Inc. (NYSE: MRK) has explored a potential acquisition of Swiss biotech firm MoonLake Immunotherapeutics in a deal valued at over $3 billion, aiming to strengthen its drug pipeline.

Merck is a clear Buy at current valuations for long term, GARP, and dividend-focused investors, balancing between short-term support from its defensive positioning and long-term optionality.

About Merck & Co Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections.

Investing.com -- Merck KGaA (ETR:MRCG) shares fell more than 5% Thursday after the company lowered its full-year outlook, citing weak demand in its Life Science and Electronics units, despite ...

Nevertheless, Merck’s first-quarter earnings and sales beat estimates. Its blockbuster drug, Keytruda, and new products have been driving sales.

Merck’s leadership focused on the evolving product mix, supply chain strategy, and regulatory developments as primary factors influencing first quarter results.